The conventional vaccine works only for the antibodies, which are (the) bullets. Our vaccine goes after antibodies and D-cells -- the soldiers. So you have the soldiers and the bullets, which could actually go after the pathogen.

If we pick the wrong pathogen to develop a vaccine and a new strain comes out, then vaccine development is futile.

The data is truly superb, but we can't get distracted by the stock surging up or down. Drug development is a long, tortuous path, and if you lose your focus you get lost in the woods.